Thermo Fisher Scientific Inc.
TMO · Price history
Price at last available close
$693.02
+$14.42 (+2.12%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Thermo Fisher Scientific Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 4, 2026. A research update is not a new financial filing.
Who they are
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases.
How they make money
Thermo Fisher Scientific provides analytical instruments, laboratory equipment, software, services, and consumables to scientific research, healthcare, industrial, and safety markets. The company generates revenue through the sale of these products and the provision of specialized pharmaceutical and laboratory services to global customers.
Products & services
Analytical instruments, laboratory equipment, reagents, consumables, software, and pharmaceutical services including clinical trials and contract development and manufacturing.
Brands & revenue mix
Flagship brand for analytical instruments and laboratory equipment.
Separate brand revenue is not available in this research.Source
Primary channel for laboratory supplies and distribution.
Separate brand revenue is not available in this research.Source
Clinical research and pharmaceutical development services.
Separate brand revenue is not available in this research.Source
Contract development and manufacturing services.
Separate brand revenue is not available in this research.Source
Specialized life sciences instrumentation.
Separate brand revenue is not available in this research.Source
Life sciences reagents and consumables.
Separate brand revenue is not available in this research.Source
Cell culture media and reagents.
Separate brand revenue is not available in this research.Source
Laboratory support and maintenance services.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
The company does not disclose a single customer that accounts for a material portion of its total revenue as of the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Raw material and component suppliers — The company relies on various third-party suppliers for raw materials and components; specific supplier names are not disclosed.Source
Competitors
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
35
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
64
Fair
Financial Strength
59
Business Quality / Moat
59
Management
82
Growth Quality
48
Risk / Durability
80
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
30
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
37/100
Building Historical Record
Model Score 37/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for TMO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can TMO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is TMO's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is TMO's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify TMO's current valuation?
Essential Investment Snapshot
Wall Street Score
35
Opportunity Score
30
Market Cap
$256.24B
P/E Ratio
36.5
EPS
$18.99
52-Week High
$705.79
52-Week Low
$435.27
Beta
0.88
Intrinsic Value
$161.41
Analyst Target
$730.00
Shares Outstanding
377.0M
Total Revenue
$47.35B
Total Debt
$41.37B
Reported Dividend Yield
0.25%
Liquidation Value / Share
$145.27
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for TMO
Detected from reported data — verify before acting.Dividend history reported
The provider reports a dividend yield. Confirm the latest declaration before treating it as a current payment.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on TMO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Broad portfolio of industry-leading brands.
- +Global commercial reach and scale.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Macroeconomic conditions affecting research and government funding.
- −Integration risks associated with acquisitions.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
35
Oct 22, 2026
Change
Unchanged
Current Score
35
Oct 28, 2026
Category Changes
TMO score was unchanged.
Projected Score
Projected Score
38
Projected Change
+3.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 3.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$693.02
Model Intrinsic Value
$161.41
Difference
+$531.61
+329.3% vs IV
Margin of Safety
-329.3%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.35B | $44.56B | $42.88B | $42.86B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $27.73B | $26.32B | $25.15B | $25.66B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $19.62B | $18.24B | $17.73B | $17.19B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $1.41B | $1.40B | $1.39B | $1.34B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $7.92B | $8.73B | $8.68B | $8.41B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $11.11B | $10.13B | $10.07B | $9.75B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $11.24B | $11.47B | $11.80B | $11.20B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $8.52B | $8.11B | $7.66B | $7.45B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $1.54B | $1.42B | $1.65B | $1.49B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $7.87B | $7.27B | $7.00B | $6.24B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $742.0M | $547.0M | $657.0M | $284.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $7.08B | $6.74B | $6.33B | $6.00B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $18.99 | $17.77 | $16.58 | $15.53 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 370M | 376M | 382M | 386M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 371M | 377M | 383M | 388M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$12.14B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$4.64
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+15.9%
Cash Change
+175.5%
Margin Change
-0.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels. Pressure indicators included debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 9.1%. EPS increased 8.7%. Cash increased 175.5%. Total debt increased 15.9%. Net income margin declined by 0.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
60
Smart Money
60
Number of Gurus
9
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
A dividend is reported, but detailed payment history is temporarily unavailable or awaiting refresh.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
Parnassus Value Equity Fund Q3 2026 Portfolio Review
Is TMO Overvalued? DCF Says Worth $352
Baron Health Care Fund Q3 2026 Top Contributors And Detractors
Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More
Rumor Mill · TMO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial